---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-23-000004"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T06:01:43.490206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer FY2022 revenue record $100.3B, adj. EPS $6.58; FY2023 guidance $67-71B rev, adj. EPS $3.25-3.45

## Summary
- Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.
- Q4 revenues $24.3B, reported EPS $0.87, adjusted EPS $1.14.
- FY2023 revenue guidance $67-71B (down ~31%), adjusted EPS $3.25-3.45 (down ~49% operational).
- Excluding COVID products, Pfizer expects 7-9% operational revenue growth in 2023.
- Completed ~$26B in acquisitions in 2022 (Biohaven, Arena, GBT); $9B dividends, $2B share repurchases.

## SEC filing metadata
- accession: 0000078003-23-000004
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/pfe-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-23-000004
- JSON: https://secwatch.observer/filing/0000078003-23-000004.json
- Plain text: https://secwatch.observer/filing/0000078003-23-000004.txt

## Key facts
- Earnings Releases
  PFIZER INC reported Full-Year 2022 results: revenue $100.3 Billion, EPS $5.47.
  - Period: Full-Year 2022
  - Revenue: $100.3 Billion
  - EPS: $5.47
  - Result: reported results
  source text: Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 2% Operationally ▪ Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm
- Earnings Releases
  PFIZER INC reported Full-Year 2023 results: revenue $67.0 to $71.0 Billion, EPS $3.25 to $3.45. Guidance initiated.
  - Period: Full-Year 2023
  - Revenue: $67.0 to $71.0 Billion
  - EPS: $3.25 to $3.45
  - Guidance: initiated
  - Result: guidance update
  source text: ▪ Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm
- Earnings Releases
  PFIZER INC reported Fourth-Quarter 2022 results: revenue $24.3 Billion, EPS $0.87.
  - Period: Fourth-Quarter 2022
  - Revenue: $24.3 Billion
  - EPS: $0.87
  - Result: reported results
  source text: Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer ▪ Fourth-Quarter 2022 Reported Diluted EPS (2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS (3) of $1.14, Up 45% Year-Over-Year
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.